Wire · operational-macro
Dr Reddy's gets tentative US FDA nod for generic HIV prevention
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
Dr Reddy's has received tentative approval from the US FDA for a generic version of the HIV prevention drug lenacapavir, enabling sales in many low- and middle-income countries but not in the US due to patent restrictions. This approval is expected to accelerate access to the drug in around 120 countries and reduce costs significantly compared to the branded version.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can enter markets in low- and middle-income countries faster by using US FDA tentative approvals as a regulatory shortcut. Your generic drug pricing now faces a stark benchmark against branded alternatives priced thousands of dollars higher.
◆ Coverage
1 source · 2 Nov 2026
◆ Related on Wire
◆ Topics